Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

Bibliography

• Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 2013;43(3):504-13
   PubMed Web of Science ®Google Scholar
• Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud 2011;8(3):348-54
   PubMedGoogle Scholar
• Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2011;2(3):133-45
   PubMedGoogle Scholar
• Bailey CJ, Aschner P, Del Prato S, et al. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res 2013;
   Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96
   PubMed Web of Science ®Google Scholar
• NICE. The management of type 2 diabetes. [CG87]. National Institute for Health and Care Excellence; London: 2009
   Google Scholar
• Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J 2012;27(4):269-73
   PubMedGoogle Scholar
• Scheen AJ. Use of oral glucose-lowering agents in patients with renal impairment. Rev Med Suisse 2012;8(351):1614-20
   PubMedGoogle Scholar
• Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368(9548):1681-8
   PubMed Web of Science ®Google Scholar
• Gordon J, Evans M, McEwan P, et al. Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom. Diabetes Ther 2013;4(1):51-66
   PubMed Web of Science ®Google Scholar
• Heinzmann S. Diabetes forecast: Market overview and context. Datamonitor Healthcare 2012.
   Google Scholar
• Henry C. Diabetes Treatment: Unmet Needs. Datamonitor Healthcare 2011
   Google Scholar
• Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49(5):930-6
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33(1):119-24
   PubMed Web of Science ®Google Scholar
• Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008;31(8):1672-8
   PubMed Web of Science ®Google Scholar
• Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008;29(1):12-20
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170(14):1191-201
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52(1):17-30
   PubMed Web of Science ®Google Scholar
• Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147(8):578-81
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373(9681):2125-35
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53(7):1258-69
   PubMed Web of Science ®Google Scholar
• FDA. Statistical review and evaluation: pioglitazone meta-analyses. 2010. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226071.pdf
   Google Scholar
• Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013;27(3):280-6
   PubMed Web of Science ®Google Scholar
• Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280(1):F10-18
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261(1):32-43
   PubMed Web of Science ®Google Scholar
• Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007;106):S27-35
   Google Scholar
• Vestri S, Okamoto MM, de Freitas HS, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001;182(2):105-12
   PubMed Web of Science ®Google Scholar
• Freitas HS, Anhe GF, Melo KF, et al. Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008;149(2):717-24
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54(12):3427-34
   PubMed Web of Science ®Google Scholar
• Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5(1):133-41
   PubMed Web of Science ®Google Scholar
• Lee H, Han KH, Park HW, et al. Familial renal glucosuria: a clinicogenetic study of 23 additional cases. Pediatr Nephrol 2012;27(7):1091-5
   PubMed Web of Science ®Google Scholar
• Powell DR, Dacosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 2013;304(2):E117-30
   PubMed Web of Science ®Google Scholar
• Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79(5):1510-15
   PubMed Web of Science ®Google Scholar
• Osorio H, Coronel I, Arellano A, et al. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012;2012:542042
   PubMed Web of Science ®Google Scholar
• Osorio H, Coronel I, Arellano A, et al. Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract 2012;97(2):276-82
   PubMed Web of Science ®Google Scholar
• Heinzmann S. Diabetes Pipeline: Product Classes. Datamonitor Healthcare 2012
   Google Scholar
• Hussey EK, Dobbins RL, Stoltz RR, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 2010;50(6):636-46
   PubMed Web of Science ®Google Scholar
• Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010;50(6):623-35
   PubMed Web of Science ®Google Scholar
• Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 2009;618(1-3):98-104
   PubMed Web of Science ®Google Scholar
• Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609(1-3):148-54
   PubMed Web of Science ®Google Scholar
• Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327(1):268-76
   PubMed Web of Science ®Google Scholar
• Sigafoos JF, Bowers GD, Castellino S, et al. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos 2012;40(11):2090-101
   PubMed Web of Science ®Google Scholar
• Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38(3):405-14
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Benito MP, et al. The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Griffen SC, et al. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab 2013;15(3):280-3
   PubMed Web of Science ®Google Scholar
• Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013;15(5):432-40
   PubMed Web of Science ®Google Scholar
• Calado J. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. IDrugs 2009;12(12):785-98
   PubMed Web of Science ®Google Scholar
• Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012;20(8):1645-52
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32(4):650-7
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223-33
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156(6):405-15
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35(7):1473-8
   PubMed Web of Science ®Google Scholar
• Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72(17):2289-312
   PubMed Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34(9):2015-22
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97(3):1020-31
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14(11):990-9
   PubMed Web of Science ®Google Scholar
• Langkilde AM. Abstract 8947: A Meta-Analysis of Cardiovascular Outcomes in Clinical Trials of Dapagliflozin. Circulation Session Title: Treating Patients with Diabetes: Effect on CV Risk and Disease 2011
   Google Scholar
• Smith SA. Still uncertain about sodium-glucose cotransporter inhibitors despite 2 centuries of study. Ann Intern Med 2012;156(6):466-7
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36(8):2154-61
   PubMed Web of Science ®Google Scholar
• Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14(6):539-45
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15(5):463-73
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28(7):1173-8
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012;28(7):1167-71
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35(6):1232-8
   PubMed Web of Science ®Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14(1):83-90
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, Randomised, Placebo-Controlled Study of the SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes. Diabetes Obes Metab 2013;15(8):721-8
   PubMed Web of Science ®Google Scholar
• Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2013;15(4):316-23
   PubMed Web of Science ®Google Scholar
• Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 2012;29(10):889-99
   PubMed Web of Science ®Google Scholar
• Imamura M, Nakanishi K, Suzuki T, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 2012;20(10):3263-79
   PubMed Web of Science ®Google Scholar
• Tahara A, Kurosaki E, Yokono M, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci 2012;120(1):36-44
   PubMed Web of Science ®Google Scholar
• Wilding JP, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2013;15(5):403-9
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, van Dijk J, Collins C, et al. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther 2012;34(8):1761-71
   PubMed Web of Science ®Google Scholar
• Ohtake Y, Sato T, Kobayashi T, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012;55(17):7828-40
   PubMed Web of Science ®Google Scholar
• Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012;341(3):692-701
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Kato M, Ozawa K, et al. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. J Pharm Sci 2012;101(11):4347-56
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Kato M, Suzuki M, et al. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J Pharmacol Exp Ther 2013;
   PubMedGoogle Scholar
• Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011;164(1):181-91
   PubMed Web of Science ®Google Scholar
• Kakinuma H, Oi T. Hashimoto-Tsuchiya Y, et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucito l (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53(8):3247-61
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92(2):158-69
   PubMed Web of Science ®Google Scholar
• Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 2013;345(2):250-9
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 2013;35(3):273-85; e7
   PubMed Web of Science ®Google Scholar
• Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects. Drug Metab Dispos 2013;41(2):445-56
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos 2011;39(9):1609-19
   PubMed Web of Science ®Google Scholar
• Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61(9):2199-204
   PubMed Web of Science ®Google Scholar
• Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2012;342(2):288-96
   PubMed Web of Science ®Google Scholar
• Moriya R, Shirakura T, Ito J, et al. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 2009;297(6):E1358-65
   PubMed Web of Science ®Google Scholar
• Ikumi Y, Kida T, Sakuma S, et al. Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na+/glucose cotransporter (SGLT1) in the small intestine. J Control Release 2008;125(1):42-9
   PubMed Web of Science ®Google Scholar
• Sabino-Silva R, Alves-Wagner AB, Burgi K, et al. SGLT1 protein expression in plasma membrane of acinar cells correlates with the sympathetic outflow to salivary glands in diabetic and hypertensive rats. Am J Physiol Endocrinol Metab 2010;299(6):E1028-37
   PubMed Web of Science ®Google Scholar
• Wright EM, Loo DD, Hirayama BA, Turk E. Surprising versatility of Na+-glucose cotransporters: SLC5. Physiology (Bethesda) 2004;19:370-6
   PubMed Web of Science ®Google Scholar
• Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012;9(2):117-23
   PubMed Web of Science ®Google Scholar
• Home P. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes. Diabetes Technol Ther 2012;14(Suppl 1):S33-42
   PubMedGoogle Scholar
• Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:313-27
   PubMedGoogle Scholar
• Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012;32(1):80-94
   PubMed Web of Science ®Google Scholar
• Carlson GF, Tou CK, Parikh S, et al. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther 2011;2(3):123-32
   Google Scholar
• Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy? PLoS One 2013;8(2):e54442
   PubMed Web of Science ®Google Scholar
• Komala MG, Panchapakesan U, Pollock C, Mather A. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 2013;22(1):113-19
   PubMed Web of Science ®Google Scholar
• Zanardi TA, Han SC, Jeong EJ, et al. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther 2012;343(2):489-96
   PubMed Web of Science ®Google Scholar
• Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95(1):34-42
   PubMed Web of Science ®Google Scholar